tbuckley/cabot-search huggingface dataset:
A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B cell lymphoma highlights challenges in translation from mouse to human studies
Authors: Tanaya Shree, Debra Czerwinski, Sarah Haebe, Anuja Sathe, Sue Grimes, Brock Martin, Michael Ozawa, Richard Hoppe, Hanlee Ji, Ronald Levy
Journal: Clinical Cancer Research (2025)

Abstract Purpose: Activating T cell costimulatory receptors is a promising approach for cancer immunotherapy. In preclinical work, adding an OX40 agonist to in situ vaccination (ISV) with SD101, a TLR9 agonist, was curative in a mouse model of lymphoma. We sought to test this combination in a Phase I clinical trial for patients with low-grade B cell lymphoma. Patients and Methods: We treated 14 patients with low-dose radiation, intratumoral SD101, and intratumoral and intravenous BMS986178, an agonistic anti-OX40 antibody. The primary outcome was safety. Secondary outcomes included overall response rate and progression-free survival. Results: Adverse events were consistent with prior experience with low-dose radiation and SD101. No synergistic or dose-limiting toxicities were observed. One patient had a partial response, and 9 patients had stable disease, a result inferior to our experience with TLR9 agonism and low-dose radiation alone. Flow cytometry and single cell RNA sequencing of serial tumor biopsies revealed that T and NK cells were activated after treatment. However, high baseline OX40 expression on T follicular helper and T regulatory type 1 cells, as well as high post-treatment soluble OX40, shed from these T cells upon activation, associated with progression-free survival of less than 6 months. Conclusions: Clinical results of T cell costimulatory receptor agonism have now repeatedly been inferior to the motivating preclinical results. Our study highlights potential barriers to clinical translation, particularly differences in preclinical and clinical reagents and the complex biology of these coreceptors in heterogenous T cell subpopulations, some of which may antagonize immunotherapy.
Structurally-oriented classification of <i>FOXA1</i> alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes
Authors: Justin Hwang, Pornlada Likasitwatanakul, Sachin Kumar Deshmukh, Sharon Wu, Jason J. Kwon, Eamon Toye, David Moline, Mark G. Evans, Andrew Elliott, Rachel Passow, Christine Luo, Emily John, Nishant Gandhi, Rana R. McKay, Elisabeth I. Heath, Chadi Nabhan, Natalie Reizine, Jacob J. Orme, Josep M. Domingo Domenech, Oliver Sartor, Sylvan C. Baca, Scott M. Dehm, Emmanuel S. Antonarakis
Journal: Clinical Cancer Research (2025)

Abstract Purpose: 10-15% of prostate cancers (PCa) harbor recurrent FOXA1 aberrations whereby the alteration type and the effect on the forkhead( FKH) domain impacts protein-function. We developed a FOXA1 classification system to inform clinical management. Experimental Design: 5,014 PCa were examined using whole exome and transcriptome sequencing from the Caris database. We denoted class 1 FOXA1 alterations as missense and in-frame insertions/deletions with subclasses oriented with respect to the FKH domain: these were in the first part of the FKH domain (class 1A: amino acids [AA] 168-246), within the Wing2 region of FKH (class 1B: AA 247-269), or outside FKH (class 1C: AA 1-167, 270+). Two hotspot missense mutations at R219 were denoted class 2. Class 3 included predicted-truncating mutations with subclasses partitioned based on the FKH domain (class 3A: AA 1-269, class 3B: AA 270+). Class 4 represented FOXA1 amplifications. Real-world overall survival and therapy outcomes were determined from insurance claims. Results: FOXA1 alterations did not influence survival when considered in aggregate, but had distinct prognostic effects when stratified by class. Class 1A alterations were associated with overall improved survival (HR=0.57, p=0.03); a similar trend was seen with Class 1B (HR=0.88, p=0.07). Conversely, class 1C exhibited worse survival upon 2nd-generation androgen receptor signaling inhibitor (ARSI) treatment (HR=1.93, p&amp;lt;0.001). Class 2 mutations (R219C/S) were enriched in neuroendocrine prostate cancers and were associated with overall poor survival (HR=2.05, p&amp;lt;0.001) and worse outcomes to first-line androgen-deprivation therapies (HR=2.5, p&amp;lt;0.001). Class 3A alterations indicated improved survival (HR=0.70; p=0.01) whereas class 3B alterations portended poor outcomes (HR=1.50; p&amp;lt;0.001). Amplifications (class 4) indicated poor outcomes (HR=1.48; p=0.02). Molecularly, different FOXA1 alteration classes harbored distinct mutational and immunologic features as well as unique transcriptional programs. Finally, relative to European-Americans, African-Americans had increased class 1C alterations whereas Asian-Pacific patients had increased class 1B alterations. Conclusions: FOXA1alterations should not be interpreted in aggregate, as different classes are associated with divergent molecular features and clinical outcomes. Our revised classification schema facilitates clinical decision making for PCa patients and uncovers important racial differences.
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer
Authors: Rachel O. Abelman, Bogang Wu, Haley Barnes, Arielle Medford, Bryanna Norden, Annika Putur, Elena Bitman, Win Thant, Ting Liu, Caroline Weipert, Geoffrey Fell, Laura M. Spring, Seth Wander, Beverly Moy, Neelima Vidula, Steven J. Isakoff, Andreas Varkaris, Dejan Juric, Ryan Corcoran, Leif W. Ellisen, Aditya Bardia
Journal: Clinical Cancer Research (2025)

Abstract Purpose: Antibody-drug conjugates (ADCs) harboring topoisomerase I (TOP1) inhibitor payloads have improved survival for patients with metastatic breast cancer (MBC). However, knowledge of ADC resistance mechanisms and potential impact on sequential use of ADCs is limited. Here, we report the incidence and characterization of TOP1 mutations arising in the setting of ADC resistance in MBC. Methods: Patients with MBC treated with ADCs with available post-treatment plasma-based genotyping were included. TOP1 mutation incidence, mutant allele frequency (MAF) and functional characterization were assessed, and incidence was compared to that in MBC patients not receiving ADC treatment and in The Cancer Genome Atlas (TCGA). Results: Plasma-based genotyping identified distinct TOP1 mutations (S57C, R364H, W401C, G359E) in 12.9% of patients (4/31) at time of disease progression on ADC, compared to 0.7% (3/420) in non-ADC treated MBC patients and 0.5% reported in TCGA. Appearance of mutations was associated with clinical cross-resistance, as median duration on first ADC was 455 days versus 52 days for second ADC. Functional characterization of three novel TOP1 mutant proteins demonstrated that all exhibited reduced enzymatic activity, attenuated covalent DNA binding, and resistance to TOP1 inhibitor ADC payloads SN38 and Deruxtecan. Conclusions: We describe the recurrent emergence of functionally altered, resistance-associated TOP1 mutations in vivo under selective pressure from ADCs, and the potential impact on mediating cross-resistance to sequential ADCs. TOP1 mutation may represent a biomarker of resistance in this setting, and additional work is needed to optimize biomarkers and ADC payload design to improve outcomes for sequential use of ADCs.
MICAL2 Promotes Pancreatic Cancer Growth and Metastasis
Authors: Bharti Garg, Sohini Khan, Asimina S. Courelli, Ponmathi Panneerpandian, Deepa Sheik Pran Babu, Evangeline S. Mose, Kevin Christian Montecillo. Gulay, Shweta Sharma, Divya Sood, Alexander T. Wenzel, Alexei Martsinkovskiy, Nirakar Rajbhandari, Jay Patel, Dawn Jaquish, Edgar Esparza, Katelin Jaque, Neetu Aggarwal, Guillem Lambies, Anthony D’Ippolito, Kathryn Austgen, Brian Johnston, David A. Orlando, Gun Ho Jang, Steven Gallinger, Elliot Goodfellow, Pnina Brodt, Cosimo Commisso, Pablo Tamayo, Jill P. Mesirov, Hervé Tiriac, Andrew M. Lowy
Journal: Cancer Research (2025)

Abstract Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid cancers; thus, identifying more effective therapies is a major unmet need. In this study, we characterized the super enhancer (SE) landscape of human PDAC to identify drivers of the disease that might be targetable. This analysis revealed MICAL2 as a super enhancer-associated gene in human PDAC, which encodes the flavin monooxygenase MICAL2 that induces actin depolymerization and indirectly promotes SRF transcription by modulating the availability of serum response factor coactivators myocardin-related transcription factors (MRTF-A and MRTF-B). MICAL2 was overexpressed in PDAC, and high MICAL2 expression correlated with poor patient prognosis. Transcriptional analysis revealed that MICAL2 upregulates KRAS and EMT signaling pathways, contributing to tumor growth and metastasis. In loss and gain of function experiments in human and mouse PDAC cells, MICAL2 promoted both ERK1/2 and AKT activation. Consistent with its role in actin depolymerization and KRAS signaling, loss of MICAL2 also inhibited macropinocytosis. MICAL2, MRTF-A, and MRTF-B influenced PDAC cell proliferation and migration and promoted cell cycle progression in vitro. Importantly, MICAL2 supported in vivo tumor growth and metastasis. Interestingly, MRTF-B, but not MRTF-A, phenocopied MICAL2-driven phenotypes in vivo. This study highlights the multiple ways in which MICAL2 impacts PDAC biology and provides a foundation for future investigations into the potential of targeting MICAL2 for therapeutic intervention.
Facts and hopes in neoadjuvant immunotherapy combinations in resectable non-small-cell lung cancer
Authors: Martin Schuler
Journal: Clinical Cancer Research (2025)

Abstract Antibodies targeting immune checkpoints, such as PD-1, PD-L1, or CTLA-4, have transformed the treatment of patients with lung cancers. Unprecedented rates of durable responses are achieved in an imperfectly characterized population of patients with metastatic disease. More recently, immune checkpoint inhibitors have been explored in patients with resectable non-small-cell lung cancers. Following a traditional paradigm, antibody therapies were first studied in the adjuvant setting, after surgery and chemotherapy. Pivotal trials supported global approvals of the PD-L1/-1 antibodies atezolizumab and pembrolizumab in this setting. Exciting observations were made when checkpoint inhibitors were moved to the preoperative window: Several signal-finding studies explored a limited number of cycles prior to surgery, and reproducibly reported complete or major histopathological responses. So far, six published phase III trials have demonstrated the superiority of combining the PD-1/-L1 antibodies nivolumab, pembrolizumab, durvalumab, tislelizumab or toripalimab with 3 to 4 courses of preoperative platinum-based chemotherapy over preoperative chemotherapy alone in terms of response rates and survival endpoints. Those patients achieving complete or major histopathological responses experienced particularly favorable long-term outcomes. It is yet unclear, whether there is true synergism between immunotherapy and chemotherapy, and whether outcomes are further improved by adding postoperative checkpoint inhibition. While these pivotal trials qualify neoadjuvant chemo-immunotherapy as another option in curative lung cancer treatment, there is hope that the chemotherapy backbone will be ultimately replaced by rationally selected and targeted combination partners. Here, the current status and future avenues of neoadjuvant combination immunotherapies in patients with non-small-cell lung cancer are reviewed.
Injectable thermosensitive antibiotic-laden chitosan hydrogel for regenerative endodontics
Authors: Alexandre Henrique Dos Reis-Prado, Maedeh Rahimnejad, Renan Dal-Fabbro, Priscila Toninatto Alves de Toledo, Caroline Anselmi, Pedro Henrique Chaves de Oliveira, J Christopher Fenno, Luciano Tavares Angelo Cintra, Francine Benetti, Marco C Bottino
Journal: Bioactive Materials (2025)
bFGF-Chitosan “brain glue” promotes functional recovery after cortical ischemic stroke
Authors: Jiao Mu, Xiang Zou, Xinjie Bao, Zhaoyang Yang, Peng Hao, Hongmei Duan, Wen Zhao, Yudan Gao, Jinting Wu, Kun Miao, Kwok-Fai So, Liang Chen, Ying Mao, Xiaoguang Li
Journal: Bioactive Materials (2025)
Hypoglycemic effect of <i>C. butyricum</i> -pMTL007-GLP-1 engineered probiotics on type 2 diabetes mellitus
Authors: Dexi Zhou, Shengjie Li, Gang Hu, Yufan Wang, Zhanghua Qi, Xuan Xu, Jing Wei, Qiong Liu, Tingtao Chen
Journal: Gut Microbes (2025)

Diabetes mellitus (DM) is a complex metabolic disease characterized by hyperglycemia. Recently, the incidence of diabetes has increased exponentially, and it is estimated to become the seventh leading cause of global mortality by 2030. Glucagon-like peptide-1 (GLP-1), a hormone derived from the intestine, has been demonstrated to exert remarkable hypoglycemic effects. However, its limitation lies in its short plasma half-life, necessitating the continuous intravenous injection of GLP-1 drugs to achieve efficacy. Here, we engineered Clostridium butyricum to continuously express and deliver GLP-1 (denoted as Cb-GLP-1), and assessed its therapeutic efficacy in type 2 diabetes mellitus (T2DM) mice. We demonstrated that administration of Cb-GLP-1 effectively lowered blood glucose levels, regulated dyslipidemia, and ameliorated hepatic impairment in T2DM mice. Furthermore, Cb-GLP-1 treatment facilitated insulin secretion by retarding islet cell apoptosis and activating the glucagon-like peptide 1 receptor/adenylate cyclase/protein kinase A (GLP-1 R/AC/PKA) signaling pathway. Gut microbiota analysis revealed that Cb-GLP-1 restored gut homeostasis disrupted in T2DM mice, as indicated by the decreased abundance of Lactobacillus and Providencia genera in response to Cb-GLP-1 treatment. Collectively, the intestinal microbiota regulation and hypoglycemic effect of the engineered strain Cb-GLP-1 presents a promising approach for diabetes management.
Galvanic Cell‐Stimulated Mesenchymal Stem Cell Mesh for Enhanced Pelvic Organ Prolapse Treatment
Authors: Ao Xiao, Jian Wang, Xi Chen, Han Wu, Xinran Jiang, Yaqin Zhao, Zhenzhen Wu, Chen Wang, Xingfu Wei, Yannan Sheng, Jiali Niu, Yongyan Hu, Haixiang Su, Qing Liu, Lingqian Chang
Journal: Advanced Healthcare Materials (2025)

Implantation of a mesh loaded with mesenchymal stem cells (MSCs) is a common approach for the treatment of pelvic organ prolapse (POP). The mesh provides effective support to pelvic floor, enhancing muscle contraction of pelvic organs while reducing inflammation. In this study, a fully degradable mesh is designed for the treatment of POP, utilizing MSCs stimulated by a galvanic battery-powered electric field. The bioelectronic mesh consists of two parts: a galvanic cell film and a porous hydrogel loaded with MSCs. The battery film has a flexible substrate, on which Zinc and Molybdenum film electrodes form a galvanic cell that discharges at up to 1.2 V, stimulating cell proliferation and migration of the MSCs pre-loaded in the hydrogel. The hydrogel provides anchoring and growth sites for the MSCs. The bioelectronic mesh elevates the production of elasticity-related and healing-related factors, enhancing the strength and elasticity of the pelvic tissue and promoting tissue regeneration for POP repair. Compared to traditional stem cell therapy, the local stimulation strategy significantly reduces inflammation in pelvic tissues. In addition, the bioelectronic mesh completely degrades after in vivo application, which avoids risks caused by surgical removal, demonstrating good biocompatibility in the implanted mesh.
Prognosis of Cardiovascular Conditions Noninvasively Using Printable Elastomeric Electronic Skin
Authors: Muthamil Selvan T, Titash Mondal
Journal: Advanced Healthcare Materials (2025)

Lack of timely prognosis of cardiovascular condition (CVC) is resulting in increased mortality across the globe. Currently, available techniques are confined to medical facilities and need the intervention of specialists. Frequently, this impedes timely treatment, driven by socioeconomic factors. Consequently, the disease transcends toward incurable complications. In such a scenario, point-of-care diagnostic tools can help with prognosis at an early stage. Albeit there are such tools available, it is imperative to develop affordably in uncomplicated manufacturing techniques and should have simple readout and analysis modules for monitoring CVC. Accordingly, the solvent-free manufacturing of stencil printable liquid elastomer-carbon nanotube electronic skin-based strain sensor, capable of accurately detecting pulse (at different positions) and other parameters like augmentation index and stiffness index of artery related to the CVC, is reported. The Poincare plot, derived from the recorded data, measures heart rate variability, a key indicator linked to mortality. Thanks to the staggering linearity, gauge factor of 234.26, fast response time of 85 ms (measured from pulse data), and cyclic stability (over 500 cycles), assist in the ease of detection of vital parameters. Furthermore, the sensor patch demonstrates its capability to acquire pulse waves under different real-time artery conditions using cuff-based pressure applications.
International multicenter validation of AI-driven ultrasound detection of ovarian cancer
Authors: Filip Christiansen, Emir Konuk, Adithya Raju Ganeshan, Robert Welch, Joana Palés Huix, Artur Czekierdowski, Francesco Paolo Giuseppe Leone, Lucia Anna Haak, Robert Fruscio, Adrius Gaurilcikas, Dorella Franchi, Daniela Fischerova, Elisa Mor, Luca Savelli, Maria Àngela Pascual, Marek Jerzy Kudla, Stefano Guerriero, Francesca Buonomo, Karina Liuba, Nina Montik, Juan Luis Alcázar, Ekaterini Domali, Nelinda Catherine P. Pangilinan, Chiara Carella, Maria Munaretto, Petra Saskova, Debora Verri, Chiara Visenzi, Pawel Herman, Kevin Smith, Elisabeth Epstein
Journal: Nature Medicine (2025)
Repairing a deleterious domestication variant in a floral regulator gene of tomato by base editing
Authors: Anna N. Glaus, Marion Brechet, Gwen Swinnen, Ludivine Lebeigle, Justyna Iwaszkiewicz, Giovanna Ambrosini, Irene Julca, Jing Zhang, Robyn Roberts, Christian Iseli, Nicolas Guex, José Jiménez-Gómez, Natasha Glover, Gregory B. Martin, Susan Strickler, Sebastian Soyk
Journal: Nature Genetics (2025)
Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits
Authors: Nora Scherer, Daniel Fässler, Oleg Borisov, Yurong Cheng, Pascal Schlosser, Matthias Wuttke, Stefan Haug, Yong Li, Fabian Telkämper, Suraj Patil, Heike Meiselbach, Casper Wong, Urs Berger, Peggy Sekula, Anselm Hoppmann, Ulla T. Schultheiss, Sahar Mozaffari, Yannan Xi, Robert Graham, Miriam Schmidts, Michael Köttgen, Peter J. Oefner, Felix Knauf, Kai-Uwe Eckardt, Sarah C. Grünert, Karol Estrada, Ines Thiele, Johannes Hertel, Anna Köttgen
Journal: Nature Genetics (2025)

Abstract Genetic studies of the metabolome can uncover enzymatic and transport processes shaping human metabolism. Using rare variant aggregation testing based on whole-exome sequencing data to detect genes associated with levels of 1,294 plasma and 1,396 urine metabolites, we discovered 235 gene–metabolite associations, many previously unreported. Complementary approaches (genetic, computational (in silico gene knockouts in whole-body models of human metabolism) and one experimental proof of principle) provided orthogonal evidence that studies of rare, damaging variants in the heterozygous state permit inferences concordant with those from inborn errors of metabolism. Allelic series of functional variants in transporters responsible for transcellular sulfate reabsorption (SLC13A1, SLC26A1) exhibited graded effects on plasma sulfate and human height and pinpointed alleles associated with increased odds of diverse musculoskeletal traits and diseases in the population. This integrative approach can identify new players in incompletely characterized human metabolic reactions and reveal metabolic readouts informative of human traits and diseases.
Combined endurance and resistance exercise training in heart failure with preserved ejection fraction: a randomized controlled trial
Authors: Frank Edelmann, Rolf Wachter, André Duvinage, Stephan Mueller, Isabel Fegers-Wustrow, Silja Schwarz, Jeffrey W. Christle, Elisabeth Pieske-Kraigher, Melchior Seyfarth, Markus Knapp, Marcus Dörr, Kathleen Nolte, Hans-Dirk Düngen, Christoph Herrmann-Lingen, Katrin Esefeld, Andreas Hagendorff, Mark J. Haykowsky, Gerd Hasenfuss, Volker Holzendorf, Christiane Prettin, Meinhard Mende, Burkert Pieske, Martin Halle
Journal: Nature Medicine (2025)
Cerebellar Bergmann glia integrate noxious information and modulate nocifensive behaviors
Authors: Seung Ha Kim, Jaegeon Lee, Mirae Jang, Seung-Eon Roh, Soobin Kim, Ji Hwan Lee, Jewoo Seo, Jinhee Baek, Jae Yoon Hwang, In Seon Baek, Yong-Seok Lee, Eiji Shigetomi, C. Justin Lee, Schuichi Koizumi, Sun Kwang Kim, Sang Jeong Kim
Journal: Nature Neuroscience (2025)
Structured programs to train the next generation of clinician scientists
Authors: Anette Melk, Carl Grabitz, Johanna Ernst, Thorsten Saenger, Eva Degraeuwe, Beatrice Beck Schimmer, Johan Vande Walle, Karolis Ažukaitis, Berent Prakken, Elias Campo, Michela Giulia Bertero
Journal: Nature Medicine (2025)
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial
Authors: Manuel A. Anderegg, Simeon Schietzel, Matteo Bargagli, Lia Bally, Nicolas Faller, Matthias B. Moor, Grazia M. Cereghetti, Marie Roumet, Sven Trelle, Daniel G. Fuster
Journal: Nature Medicine (2025)

Efficacy of sodium-glucose cotransporter 2 inhibitors for kidney stone prevention in nondiabetic patients is unknown. In a double-blind, placebo-controlled, single-center, crossover phase 2 trial, 53 adults (≥18 and <75 years) with calcium (n = 28) or uric acid (UA; n = 25) kidney stones (at least one previous kidney stone event) without diabetes (HbA1c < 6.5%, no diabetes treatment) were randomized to once daily empagliflozin 25 mg followed by placebo or reverse (2 weeks per treatment). Randomization and analysis were performed separately for both stone types. Primary analyses were conducted in the per protocol set. Primary outcomes were urine relative supersaturation ratios (RSRs) for calcium oxalate (CaOx), calcium phosphate (CaP) and UA—validated surrogates for stone recurrence. Prespecified RSR reductions (≥15%) were met in both groups of stone formers. In patients with calcium stones, empagliflozin reduced RSR CaP (relative difference to placebo, −36%; 95% confidence interval, −48% to −21%; P < 0.001), but not RSRs CaOx and UA. In patients with UA stones, empagliflozin reduced RSR UA (−30%; 95% confidence interval, −44% to −12%; P = 0.002) but not RSRs CaOx and CaP. No serious or prespecified adverse events occurred. Thus, empagliflozin substantially reduced RSRs in nondiabetic adults with calcium and UA kidney stones. ClinicalTrials.gov registration: NCT04911660 . As part of the SWEETSTONE trial, the authors report the ability of the sodium-glucose cotransporter 2 inhibitor empagliflozin to reduce the likelihood of kidney stone formation in individuals without diabetes.
The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis
Authors: Richa Shah, Nader Mounir Hanna, Ching Ee Loo, Michael David, Allini Mafra, Hanna Fink, Ethna McFerran, Montse Garcia, Robabeh Ghodssighassemabadi, Suryakanta Acharya, Jean Niyibaga, Oliver Langselius, Clara Frick, Nwamaka Lasebikan, Jerome Vignat, Julia Steinberg, Suzanne Hughes, Colleen Elizabeth Kircher, Catherine Lindsay Goldie, Sam Egger, Richard Sullivan, Ophira Ginsburg, Freddie Bray, Michael Caruana, Harriet Hui, André Michel Ilbawi, Karen Canfell, Isabelle Soerjomataram
Journal: Nature Cancer (2025)
A feeding-induced myokine modulates glucose homeostasis
Authors: Xiaoliu Shi, Xiao Hu, Xinlei Fang, Liangjie Jia, Fangchao Wei, Ying Peng, Menghao Liu, Aibo Gao, Ke Zhao, Fengyi Chen, Xiaoli Hu, Jie Hong, Guang Ning, Yongfeng Song, Jiqiu Wang, Yiguo Wang
Journal: Nature Metabolism (2025)